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Summary Direct measurement of the reticulocyte hemoglobin content provides useful information for
the diagnosis and treatment of iron-deﬁcient states. We have examined direct measure-
ments of reticulocyte and red cell hemoglobin content on the Sysmex XE 2100 (Ret He and
RBC He respectively) and the Bayer ADVIA 2120 (CHr and CH respectively) analyzers.
Good agreement was found between Ret He and CHr (Y ¼ 1.04X ) 1.06; r
2 ¼ 0.88) and
between the RBC He and CH parameters (Y ¼ 0.93X +1 ;r
2 ¼ 0.84 n ¼ 200) in pediatric
patients and in normal adults (Ret He and CHr; Y ¼ 1.06X ) 0.43; r
2 ¼ 0.83; n ¼ 126;
RBC He and CH; Y ¼ 0.94X +1 ; r
2 ¼ 0.87; n ¼ 126). In 1500 blood samples from
patients on chronic dialysis, Ret He was compared with traditional parameters for iron
deﬁciency (serum iron <40 lg/dl, Tsat <20%, ferritin <100 ng/ml, hemoglobin <11 g/dl)
for identifying iron-deﬁcient states. Receiver operator characteristic (ROC) curve analysis
revealed values of the area under the curve for Ret He of 0.913 (P < 0.0001). With a Ret
He cutoff level of 27.2 pg, iron deﬁciency could be diagnosed with a sensitivity of 93.3%,
and a speciﬁcity of 83.2%. Ret He is a reliable marker of cellular hemoglobin content and
can be used to identify the presence of iron-deﬁcient states.
Keywords CHr, reticulocyte hemoglobin content, r-HuEpo (recombinant human erythropoietin), Iron
replacement therapy, Ret He (reticulocyte hemoglobin equivalent)
Introduction
By directly measuring the mean hemoglobin content (pg)
of red blood cell (RBC) precursors (Reticulocytes), early
stages of iron deﬁciency may be identiﬁed, at a time that
other traditional biochemical parameters are non-inform-
ative (Brugnara, 2000, 2003). The measurement of
reticulocyte hemoglobin content is a direct assessment of
the incorporation of iron into erythrocyte hemoglobin and
thus a direct estimate of the recent functional availability
of iron into the erythron (Brugnara et al., 1994c, 1997;
Buttarello et al., 2004). The mean intracellular hemo-
globin content of erythrocytes (MCH) is an all inclusive
measure of both the availability of iron over the preceding
90–120 days, and of the proper introduction of iron into
intracellular hemoglobin (Brugnara et al., 1994b,c). The
absence of signiﬁcant interferences with the exception of
concomitant alpha- or beta-thalassemia or macrocytosis,
provides another potential advantage of these hematolo-
gical markers over indirect biochemical testing, which is
affected by a variety of factors, including inﬂammation.
The CHr (mean cellular hemoglobin content of reticulo-
cytes) parameter provided by the ADVIA 120 and 2120
(Bayer Diagnostics, Tarrytown, NY, USA) was cleared by
the FDA in August 1997, for clinical application within
the USA (K#971998). Since May 2005, an equivalent
parameter, the Ret He (reticulocyte hemoglobin equival-
ent) has been available for use on the Sysmex XE 2100
(Sysmex Corporation, Kobe, Japan), broadening the avail-
ability of a tool for assessing reticulocyte hemoglobin
content (K#050589).
Cellular content of Hb can be precisely assessed by ﬂow
cytometry in mature erythrocytes as well: the RBC He
(Sysmex) and CH (Bayer) parameters express (in pg) the
mean erythrocyte hemoglobin content. Examining both
the precursors, and mature red cells provides an oppor-
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303tunity to detect and monitor acute and chronic changes in
cellular hemoglobin status.
In this report, we compare reticulocyte and red cell
measurements of Hb content provided by the ADVIA 2120
and Sysmex XE 2100 analyzers in adult and pediatric
patients and assess the diagnostic value of Ret He in a
large population of adult patients on chronic dialysis.
Materials and methods
Studies in pediatric and adult samples
Samples collected in EDTA anti-coagulant were randomly
extracted from the routine workload and run sequentially
on both the XE 2100, and ADVIA 2120. Samples were
run within 6 h of collection. The scope of the pathology
included a variety of diseases considered retrospectively
as being representative of the daily workload. Renal
disease contributed 19% of the samples, Sickle Cell
Anemia 4.5%, and Thalassemias 7%. Reference Range
data were gathered from 126 normal adult subjects, all
ﬁrst year medical students participating in a blood
drawing/analysis exercise. Studies were carried out
under IRB approved protocols S-04-07-080 and NS05-
05-005 (comparative analysis of hematology/coagulation
analyzers).
Precision analysis for Ret He and RBC He was carried
out according to NCCLS EP5 as follows: after a device
familiarization period, Quality Control material (E-Check)
was run in duplicate, twice daily, over a 20-day period.
This allowed calculation of within run precision, SD of the
run means, SD of the daily means and total imprecision.
Stability analysis for Ret He and RBC He was carried out
as follows: 10 samples were selected, ﬁve normal and ﬁve
abnormal. Aliquots of the selected samples were stored at
room temperature, and 4  C respectively. All samples were
tested at baseline, 6, 12, 24 and 48 h in order to assess
changes over time.
Studies in patients on maintenance dialysis
Blood samples (1500), utilizing residual material from the
monthly blood draw from patients undergoing routine
hemodialysis in an outpatient dialysis settings were
analyzed at Satellite Laboratories on a Sysmex XE 2100
analyzer. This observational study was performed on left-
over material, after all the clinically indicated analyses
had been performed. Samples were collected anony-
mously; no identifying information was recorded during
this study. No exclusion criteria were applied during this
study. The patients were a representative sample of US
ESRD patients with a mean age of 63.5 ± 15.4 years and
a male/female ratio of 56/44%.
Patients were managed according to the recommenda-
tions of the NKF-K/DOQI (National Kidney Foundation,
Kidney Disease Outcomes Quality Initiative) anemia
guidelines (NKF-K/DOQI, 2001). All patients were treated
with a variety of erythropoietin doses given three times a
week, at the time of hemodialysis treatment. In addition,
the majority of patients were treated with a maintenance
dose of intravenous iron (100–200 mg of iron gluconate)
weekly or every other week in order to maintain iron
stores at the recommended levels. Forty-eight percent of
the patients sampled had signiﬁcantly elevated C-reactive
protein values (>5 mg/l), consistent with the presence of
underlying inﬂammation, a common ﬁnding in this
patient population (Yeun et al., 2000). Absolute iron
deﬁciency in patients with kidney disease has been deﬁned
as serum ferritin levels <100 ng/ml and serum transferrin
saturation (Tsat) <20% (NKF-K/DOQI, 2001).
Statistical analysis
Statistical analysis was conducted with the use of Analyse-
it  statistical software add-in for Microsoft Excel (for
Windows). Receiver operating characteristic (ROC) ana-
lysis was utilized to illustrate the diagnostic performance
of ret He with ROC curves. Traditional diagnostic criteria
for Iron deﬁciency anemia diagnosis, included as criteria
for presence of disease in ROC curve generation: Serum
Iron < 40 micrograms/dl, Tsat <20%, Ferritin <100 ng/
ml, and Hemoglobin <11 g/dl). The traditional diagnostic
criteria for Functional iron-deﬁciency diagnosis used for
ROC curve generation were Tsat <20%, Ferritin 100–
800 ng/ml, and Hemoglobin <11 g/dl. The signiﬁcance of
areas under the ROC curves for ret He was assessed in
comparison with no discrimination. A ret He cutoff was
established based on the optimal combination of sensitivity
(‡80%) and speciﬁcity (‡50%), decided a priori as mini-
mum requirements of a screening test for iron deﬁciency.
Values below this cutoff were considered to be abnormal.
Results
Pediatric samples and normal adult controls studies
Figure 1 presents correlation data for reticulocyte and red
cell hemoglobin content respectively. Data were obtained
from 200 clinical samples and show good correlation
between the Ret He and ADVIA CHr (Y ¼ 1.04X ) 1.06;
r
2 ¼ 0.88) and between the RBC He and ADVIA CH
parameters (Y ¼ 0.93X +1 ;r
2 ¼ 0.84). Figure 2 shows
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controls. Figure 3 presents a plot of the difference between
ADVIA and Sysmex parameters, for both reticulocyte and
erythrocyte hemoglobin content. There is a tendency for
Ret He to yield values higher than CHr above 30 pg/cell,
whereas RBC He tends to provide values lower than CH
above 25 pg/cell.
Reference range data
Table 1 presents reference interval data gathered from
126 normal adult subjects.
Precision data
Precision data were collected over 20 days and revealed a
total Ret He Imprecision with a SD of 0.85 pg (CV 3.92%),
and a total RBC He Imprecision with a SD of 0.29 pg (CV
1.33%; Table 2).
Stability
Five normal and ﬁve abnormal samples were selected.
Aliquots of the selected samples were stored at room
temperature and 4  C respectively. All samples were tested
at baseline, 6, 12, 24 and 48 h in order to assess changes
over time. Data show that both Ret He and RBC He are
very stable, with <1SD change over 48 h in all samples
tested (room temperature and refrigerated; Table 3).
Iron-deﬁciency diagnosis study
The goal was to determine the diagnostic performance of
the Ret He parameter against the existing diagnostic tests
for iron-deﬁciency diagnosis (serum iron < 40 lg/dl, Tsat
<20%, ferritin <100 ng/ml and hemoglobin <11 g/dl;
Figure 4). ROC curve analysis revealed that by using a Ret
He cutoff level of 27.2 pg, iron deﬁciency could be
diagnosed with a sensitivity of 93.3%, and a speciﬁcity
of 83.2%. The area under the curve was 0.913
(P < 0.0001).
A similar exercise was undertaken to determine the
diagnostic performance of the Ret He parameter when
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Figure 2. Method comparison data, XE 2100 and ADVIA 2120:
top, Ret He vs. CHr; bottom RBC He vs. CH. Data were obtained
from 126 normal adults, and show good correlation between the
Ret He and ADVIA CHr (Y ¼ 1.06 ) 0.43; r
2 ¼ 0.83; n ¼ 126)
and between the RBC He and ADVIA CH (Y ¼ 0.94X +1 ;r
2 ¼
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Figure 1. Method comparison data, XE 2100 and ADVIA 2120:
top, Ret He vs. CHr; bottom RBC He vs. CH. Data were obtained
from 200 clinical samples and show good correlation between the
Ret He and ADVIA CHr (Y ¼ 1.04X ) 1.06; r
2 ¼ 0.88) and
between the RBC He and ADVIA CH (Y ¼ 0.93X +1 ;r
2 ¼ 0.84).
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functional iron deﬁciency (FID). Functional iron deﬁciency
was identiﬁed as Tsat <20%, ferritin 100–800 ng/ml, and
hemoglobin <11 g/dl. Using a ret He cutoff level of
Table 1. Reference range intervals for reticulocyte and eryth-
rocyte hemoglobin content parameters in 126 normal adults
CHr (pg) Ret He (pg) CH (pg) RBC He (pg)
Mean 31.18 32.47 30.16 29.29
SD 1.67 1.93 1.82 1.74
Min 23.3 24.1 21.8 21
Max 34.1 35.8 33.7 33
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Figure 3. In the top panel, the difference between Ret He and
CHr is plotted vs. the mean value for the two parameters. In the
bottom panel, the difference between RBC He and CH is plotted
vs. the mean value for the two parameters. Data were combined
for the 200 clinical samples and the 126 normal controls.
Table 2. Precision analysis for Ret He and RBC He parameters
Ret He
SD (pg)
Ret He
CV (%)
RBC He
SD (pg)
RBC He
CV %
Within run precision 0.32 1.49 0.27 1.23
SD of the run means 0.29 1.32 0.16 0.74
SD of the daily means 0.79 3.66 0.19 0.86
Total imprecision 0.85 3.92 0.29 1.33
Table 3. Room temperature and refrigerated stability for Ret He
and RBC He
Parameter
Change at 24 h Change at 48 h
2· Baseline
SD
Room
temp. Refrig
Room
temp. Refrig
Ret He 0.13 0.12 0.35 0.25 5.78
RBC He 0.2 0.11 0.12 0.03 3.74
Units, picograms of hemoglobin.
Fe            <40 µg/dl
Tsat         <20%
Tsat      <20%
Ferritin  100–800 ng/ml
Hemoglobin <11g/dl
Ferritin     <100 ng/ml
Hgb          <11 g/dl
Figure 4. Top: ROC curve analysis for Ret He and the diagnosis
of iron-deﬁciency anemia in hemodialysis patients. The diag-
nostic performance of Ret He in identifying iron-deﬁcient states
was compared with that of traditional parameters for iron deﬁ-
ciency (serum iron <40 lg/dl, Tsat <20%, ferritin <100 ng/ml,
hemoglobin <11 g/dl). By using a Ret He cutoff level of 27.2 pg,
iron deﬁciency could be diagnosed with a sensitivity of 93.3%,
and a speciﬁcity of 83.2%. The area under the curve was 0.913.
Bottom: ROC curve analysis for Ret He and the diagnosis of
functional iron deﬁciency in hemodialysis patients. Functional
iron deﬁciency was deﬁned tests as Tsat <20%, Ferritin 100–
800 ng/ml, and HGB <11 g/dl. The diagnostic performance of
ret He is less favorable (area under the curve 0.657).
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40.2% and a speciﬁcity of 80.3%. The area under the
curve was 0.657 (P < 0.0001).
Discussion
Measurements of reticulocyte hemoglobin content have
been shown to provide useful information in diagnosing
FID during r-HuEPO therapy (Brugnara et al., 1994a),
iron-deﬁcient states in infancy (Brugnara et al., 1999;
Ullrich et al., 2005) and response to iron therapy (Brugn-
ara et al., 1993, 1997; Thomas & Thomas, 2002). A
limitation of this approach has been the fact that these
parameters were available only on Bayer instruments.
Recently, cellular hemoglobin content parameters have
now become available on the Sysmex instruments (Canals
et al., 2005; Thomas et al., 2005).
This study shows a very good level of agreement
between the cellular Hb measurements performed with the
Sysmex XE 2100 and those performed with the Bayer
ADVIA instrument. The precision and stability of both Ret
He and RBC He are excellent: minimal variations are seen
over time in either room temperature of 4  C storage.
Normal range values for the reticulocyte and red cell
hemoglobin content parameters are superimposable
between the two different methods.
In patients on maintenance dialysis, the diagnostic
performance of Ret He, when compared to traditional
parameters for iron-deﬁciency anemia diagnosis, was
excellent, with an ROC area under the curve of 0.913
(P < 0.0001).
Iron stores estimates do not provide an assessment of
the availability of iron for introduction into erythrocyte
hemoglobin. This lead to the establishment of a concept
called functional iron-deﬁciency, and has particular
relevance in patients receiving recombinant human ery-
thropoietin (rHuEPO; Macdougall et al., 1992; Horl, 1995;
Macdougall, 1995). In anemic patients receiving thera-
peutic doses of rHuEpo, the cellular requirements for iron
are increased, and can lead to decreased iron incorpor-
ation into cellular hemoglobin, which is thought to
hamper the effectiveness of rHuEpo therapy. Patients
deemed to be functionally iron-deﬁcient during rHuEpo
therapy, are given additional iron, in an effort to
compensate for the relative deﬁciency (Macdougall et al.,
2000; Valderrabano et al., 2000). In diagnosing ‘func-
tional iron-deﬁciency’, the diagnostic performance of Ret
He, when compared with traditional parameters was not
as impressive, with a much smaller ROC area under the
curve of 0.657 (P < 0.0001). However, in the absence of
assessing the response to IV iron, there are no uniformly
accepted criteria to identify functional iron-deﬁciency
(Fishbane et al., 1997). The presence of inﬂammation
and uremia makes this diagnosis particularly challenging
for dialysis patients (Sunder-Plassmann, Spitzauer & Horl,
1997). Attempts to use the baseline Ret He results as a
tool to identify potential responders to increased IV iron
therapy were unsuccessful in the functional iron-deﬁci-
ency subgroup (data not shown). This ﬁnding suggests
that more than one sampling may be required in order to
adequately monitor responses to therapy.
In conclusion, this study shows a very good level of
agreement between cellular hemoglobin measurements
performed by two different analyzers in both reticulo-
cytes and erythrocytes. The expanded availability of
these parameters should allow further assessment of
their role in diagnosing disturbances of iron metabo-
lism and assessing response to iron supplementation
therapy.
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